Shares of American International Holdings Corp. (OTC: AMIH) may not get much investor attention, but that could be an oversight that leaves money on the table. In fact, while trading in tandem with a weakened healthcare services sector, the value proposition in AMIH could be more compelling than ever. And after launching new services and enhancing the ones they have, its mission to create shareholder value in the last two quarters of this year puts AMIH in play.
Better still, value can come sooner rather than later, with AMIH taking aim at the massive opportunities created by the digital revolution in healthcare. There, digital services are more than a revolution; it’s the norm. Everything from checking in, billing, patient visits, and test results is provided digitally. And for those that don’t understand how to use the technology, they better learn. With healthcare providers and offices getting squeezed by tight margins, practices across the country are turning digital to lessen overhead and reduce redundant costs.
It’s a necessity that AMIH wants to monetize. And they are doing so after re-prioritizing its business strategy to focus on substantial market and services opportunities exposed by the COVID-19 pandemic. Indeed, AMIH, like peers in its sector, was impacted hard by the challenges presented during the past eighteen months. Thus, AMIH has seen its share price decline in tandem with a weakening healthcare services sector.
However, from challenges come opportunities. And from oversold share prices come potentially lucrative gains. Hence, looking backward when evaluating AMIH makes little sense. This company has re-evaluated its priorities and is on a fast track to maximizing its revenue-generating potential from the $4.2 trillion US health care industry. Thus, it’s time to look forward to what this undervalued company has to offer.
Seizing Opportunities In A Changed Healthcare Landscape
While there is no upside to the ongoing pandemic, one takeaway is that it’s making the US healthcare system stronger. It exposed flaws, gaps, loopholes, and inefficiency throughout the system. It showed how simple procedures can become complicated and revealed the tremendous cost of maintaining a practice when many people work just to file claims. AMIH wants to do things in a better way. And that mission has begun.
Already an investor, developer, and asset manager diversified across the healthcare supply chain, AMIH is carving its niche in a potentially lucrative and specialized sector. Its platforms offer an impressive list of services, including telemedicine and other virtual health platforms, subscriber-based primary care, concierge medicine plans, and preventative care solutions.
They also reach into wellness-related assets such as proprietary nutrition-based products, mental & behavioral health services and are advancing a proprietary life coaching platform. And by providing its comprehensive list of services through direct-to-consumer and business-to-business distribution channels, AMIH shows that focusing on developing, acquiring, and bringing to market technologies and solutions that advance the quality of life for the global community can be a rewarding proposition.
ZipDoctor And EPIQ MD
Moreover, they are working to fix what is broken. The pandemic exposed shortcomings in the treatment sector and underscored the necessity to be truly healthy in body and mind. And with a treatment economy expected to at least double from the $4.2 trillion levels in the next ten years, being ahead of the curve can have its advantages. At least two programs are in play to capitalize on what AMIH thinks is the low-hanging fruit of opportunity.
First, the company launched ZipDoctor, a capital-efficient, digitally-based platform that affordably connects people and small businesses with healthcare practitioners. The sector isn’t new; by 2021, tele-medicine has surged to a more than $194 billion industry. And ZipDoctor wants a piece. Better still, they think they can get it after market-testing results led to AMIH building and launching EPIQ MD, which the company believes represents the next generation in tele-health and wellness. It’s also more niche-focused.
Thus, rather than compete with entrenched companies like Teladoc that contract with health insurers to reduce their costs of providing primary care to their insureds, EPIQ MD is targeting a “massive niche” by reaching out to the more than 80 million US residents that are either under-insured or have no insurance at all. Try using Teledoc without insurance. It won’t happen.
Moreover, AMIH research indicated that many of its target consumers, including small businesses that want to offer provider services, will pay more for a much more comprehensive suite of wellness services. And through a monthly subscription rate starting as low as $29.95, EPIQ MD offers access to primary care physicians, mental health professionals, nutritional counseling, and deeply discounted rates to select third-party providers of prescriptions, in-person diagnostic, and lab services.
Further, AMIH expects to enhance its value by adding even more services, including functional foods, proprietary nutraceutical blends, wearables, specialized medicine, and risk mitigation services. Hence, the platform can be a substantial value driver going forward. And with the launch of EPIQ MD expected to reach a nationwide audience by the end of 2022, the dollars in play can be enormous.
The better news is that market growth, even staggered, equates to value. And with its flagship portfolio asset EPIQ MD now penetrating initial targeted markets, updates on expansion and revenue-generating catalysts may be near.
There’s more to like.
LifeGuru Targets A Growing Mental Health Issue
A second value driver comes through LifeGuru, a life coaching platform that connects people with specialized life coaches with expertise mentoring people through life’s challenges. Not only stress, either. LifeGuru services expect to touch people to counsel romance, finance, career, health, and family issues. It’s a platform that grew out of the challenges presented by COVID-19, which of course, wreaked havoc on the personal lives of more than 320 million Americans. And it still is.
And as tens of millions of people continue to be impacted, AMIH seized its opportunity to develop a platform to help coaches access new clients nationwide and match people nationwide with their optimal life coach. Better still, LifeGuru is targeting what has become a multi-billion-dollar sector opportunity. They also make it accessible and affordable.
The current business plan calls for coaches to pay a subscription fee for access to the platform and for clients to pay an affordable rate for tele-sessions. The value to AMIH comes through receiving recurring revenue for building, marketing, and managing the platform. While still a non-revenue-generating asset, AMIH is taking steps to monetize this platform sooner rather than later. Better yet, they are creating the LifeGuru platform to be globally accessible and offered in multiple languages. Thus, like EPIQ MD, news about this innovative services platform can be a value driver in the coming months. AMIH is expected to provide updates about coach recruitment and plans to begin marketing programs as early as this year. Keep in mind, while some things are better, businesses may still be operating in COVID time. Hence, timelines can be pushed back, understandably.
Still, there’s much on the plate for AMIH. The better news is that value creation is happening today. And that could make the rest of 2021 attractive from an investor’s perspective.
Creating The Platforms That Drive Growth
Undoubtedly, 2020 and 2021 presented challenging times to almost every business sector in the world. And despite the need for emergency medical services rampant, general medical practitioners and providers were impacted too. But, as noted, challenges exposed opportunities. AMIH intends to monetize several.
In focus for the remainder of this year and the start of next, expect EPIQ Innovations, the sister company to EPIQ MD, to bring a curated assortment of proprietary, in-house formulated advanced nutraceutical products to market. The mission there is to seize upon a market that exploded in value since COVID-19 as consumers have turned toward non-prescription immune-boosting and other nutraceuticals.
Also, expect growth from both ZipDoctor and EPIQ MD to drive value in the current and coming quarters. Even better, AMIH’s interest and success in acquiring and developing additional accretive businesses nourish the value equation as well. Best of all,
with Maxim Group on board, which AMIH retained for strategic guidance, the disconnect between share price and intrinsic value could be cured. With that added market expertise and its launch of EPIQ MD, that’s likely to happen. After all, that’s what they get paid to do.
Thus, as shares churn around the $0.06 level with several potential catalysts ahead, investing in deeply discounted AMIH stock may be timely. And with news potentially imminent on its EPIQ MD rollout, trading ahead of expected updates may be the best way to capture value.
Disclaimers: STM, Llc. is responsible for the production and distribution of this content. STM, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by STM, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall STM, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by STM, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. STM, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, STM, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Company Name: STM, LLC.
Contact Person: Michael Thomas
Country: United States